Altimmune (ALT) News Today $8.68 +0.28 (+3.33%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Price Target at $20.00November 23 at 3:47 AM | americanbankingnews.comAnalyzing Altimmune (NASDAQ:ALT) & Aquestive Therapeutics (NASDAQ:AQST)November 23 at 2:53 AM | americanbankingnews.comDo Redditors Think That Altimmune Inc. (ALT) Has a Big Upside Potential?November 21 at 5:40 PM | msn.comFY2024 EPS Estimates for Altimmune Reduced by HC WainwrightNovember 20 at 2:44 AM | americanbankingnews.comHC Wainwright Decreases Earnings Estimates for AltimmuneAltimmune, Inc. (NASDAQ:ALT - Free Report) - Research analysts at HC Wainwright reduced their FY2024 earnings per share estimates for Altimmune in a report released on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($1.28) per shareNovember 18, 2024 | marketbeat.comAltimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight analysts that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given aNovember 18, 2024 | marketbeat.comAltimmune's (ALT) "Buy" Rating Reiterated at HC WainwrightNovember 17, 2024 | americanbankingnews.comB. Riley Estimates Altimmune's Q1 Earnings (NASDAQ:ALT)November 16, 2024 | americanbankingnews.comUBS Group Initiates Coverage on Altimmune (NASDAQ:ALT)November 16, 2024 | americanbankingnews.comAltimmune presents data on effect of pemvidutide on inflammatory lipidsNovember 15, 2024 | markets.businessinsider.comAltimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024November 15, 2024 | globenewswire.comWhat is B. Riley's Estimate for Altimmune FY2024 Earnings?Altimmune, Inc. (NASDAQ:ALT - Free Report) - Investment analysts at B. Riley lowered their FY2024 EPS estimates for shares of Altimmune in a research note issued on Wednesday, November 13th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings per share of ($1.40) for tNovember 15, 2024 | marketbeat.comWhat is B. Riley's Estimate for Altimmune Q1 Earnings?Altimmune, Inc. (NASDAQ:ALT - Free Report) - Investment analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for shares of Altimmune in a report released on Wednesday, November 13th. B. Riley analyst M. Mamtani anticipates that the company will post earnings per share of (November 14, 2024 | marketbeat.comAltimmune's (ALT) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of Altimmune in a report on Thursday.November 14, 2024 | marketbeat.comAltimmune Third Quarter 2024 Earnings: Beats ExpectationsNovember 14, 2024 | finance.yahoo.comAltimmune provided key pipeline updates with Q3 report, says B. RileyNovember 14, 2024 | markets.businessinsider.comAltimmune call volume above normal and directionally bullishNovember 13, 2024 | markets.businessinsider.comAltimmune’s Pemvidutide Progress and Expansion: A Buy Recommendation by Patrick TrucchioNovember 13, 2024 | markets.businessinsider.comAltimmune’s pemvidutide looks differentiated among GLP-1s, says H.C. WainwrightNovember 13, 2024 | markets.businessinsider.comAltimmune: Pemvidutide As MASH Drug Could Provide Competitive EdgeNovember 13, 2024 | seekingalpha.comAltimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver HealthNovember 13, 2024 | seekingalpha.comAltimmune, Inc. (NASDAQ:ALT) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | msn.comAltimmune Reports Q3 2024 Financial Results and Advances Drug PipelineNovember 13, 2024 | markets.businessinsider.comGSA Capital Partners LLP Has $2.09 Million Holdings in Altimmune, Inc. (NASDAQ:ALT)GSA Capital Partners LLP trimmed its stake in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 30.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 339,595 shares of the company's stock after seNovember 13, 2024 | marketbeat.comAltimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding ...November 13, 2024 | finance.yahoo.comAltimmune Stock Goes Parabolic Following Q3 Results As CEO Touts 2025 As ‘Transformational Year:’ Retail UpbeatNovember 12, 2024 | msn.comAltimmune, Inc: Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial OfficerNovember 12, 2024 | finanznachrichten.deAltimmune Announces Third Quarter 2024 Financial Results and Provides a Business UpdateNovember 12, 2024 | finance.yahoo.comAltimmune initiated with a Buy at UBSNovember 12, 2024 | markets.businessinsider.comAltimmune’s Pemvidutide: A Promising Buy Rating for Metabolic Health BreakthroughsNovember 12, 2024 | markets.businessinsider.comAltimmune Target of Unusually High Options Trading (NASDAQ:ALT)Altimmune, Inc. (NASDAQ:ALT - Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 18,846 call options on the stock. This represents an increase of 185% compared to the typical daily volume of 6,618 call options.November 12, 2024 | marketbeat.comUBS Group Begins Coverage on Altimmune (NASDAQ:ALT)UBS Group began coverage on Altimmune in a research note on Tuesday. They issued a "buy" rating and a $26.00 price target on the stock.November 12, 2024 | marketbeat.comAltimmune announces inducement grants under Nasdaq listing ruleNovember 11, 2024 | markets.businessinsider.comAltimmune, Inc: Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 11, 2024 | finanznachrichten.deAltimmune Names Greg Weaver Chief Financial OfficerNovember 11, 2024 | marketwatch.comAltimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial OfficerNovember 11, 2024 | globenewswire.comAltimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 11, 2024 | globenewswire.comAltimmune (ALT) Receives a Buy from Evercore ISINovember 9, 2024 | markets.businessinsider.comMarketBeat Week in Review – 11/4 - 11/8 (ALT)Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lastsNovember 9, 2024 | marketbeat.comHow Altimmune Could Grab a Big Chunk of the GLP-1 MarketAltimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users.November 8, 2024 | marketbeat.comAltimmune announces successful completion of End-of-Phase 2 meetingNovember 7, 2024 | markets.businessinsider.comAltimmune (NASDAQ:ALT) Stock, Option ChainNovember 7, 2024 | benzinga.comAltimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of ObesityNovember 7, 2024 | globenewswire.comAltimmune to Participate at Two Upcoming Investor ConferencesNovember 6, 2024 | globenewswire.comAltimmune (ALT) to Release Quarterly Earnings on TuesdayAltimmune (NASDAQ:ALT) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports.November 5, 2024 | marketbeat.comAltimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024November 4, 2024 | globenewswire.comAltimmune (NASDAQ:ALT) Shares Up 7% - Here's What HappenedAltimmune (NASDAQ:ALT) Stock Price Up 7% - Here's WhyOctober 29, 2024 | marketbeat.comRegulatory And Clinical Catalysts Ahead For AltimmuneOctober 28, 2024 | seekingalpha.comAltimmune, Inc. (NASDAQ:ALT) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven research firms that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, four have issued a buy rating and oneOctober 24, 2024 | marketbeat.comSG Americas Securities LLC Sells 220,135 Shares of Altimmune, Inc. (NASDAQ:ALT)SG Americas Securities LLC lowered its stake in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 86.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 34,436 shares of the company's stock after selling 220,135 shares during the quarter.October 23, 2024 | marketbeat.com Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. ALT Media Mentions By Week ALT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALT News Sentiment▼-0.120.49▲Average Medical News Sentiment ALT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALT Articles This Week▼119▲ALT Articles Average Week Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Arbutus Biopharma News Kamada News Fulcrum Therapeutics News BeyondSpring News Unity Biotechnology News MEI Pharma News Longboard Pharmaceuticals News IDEAYA Biosciences News Arrowhead Pharmaceuticals News Wave Life Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
